MOUNTAIN VIEW, Calif., Dec. 04, 2024 (GLOBE NEWSWIRE) -- December 4, 2024 – NeuroPace, Inc. (NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today ...

First of its kind, multi-year collaboration leverages RNS System’s data to track responses of implanted RNS System patients enrolled in a biotechnology company’s clinical trial In strategic data ...

US-based NeuroPace has reported the initial primary endpoint one-year outcomes from the two-year NAUTILUS trial of the RNS System for treating individuals with drug-resistant idiopathic generalised ...

NeuroPace, Inc. (NASDAQ:NPCE) released preliminary primary endpoint one-year results of the two-year NAUTILUS study evaluating safety and effectiveness of the RNS System for drug-resistant idiopathic ...

Tuesday saw UBS begin coverage on NeuroPace Inc (NASDAQ:NPCE), a medical technology company specializing in responsive neuromodulation systems for epilepsy treatment. Analysts at UBS have given the ...

MOUNTAIN VIEW, Calif. - NeuroPace, Inc. (NASDAQ:NPCE), a $529 million market cap medical device company whose stock has surged over 47% in the past six months, has submitted a Premarket Approval ...

Three-year data from the largest FDA-reviewed prospective neuromodulation study of safety and effectiveness in drug-resistant focal epilepsy 1 Long-term seizure reduction with a median reduction of 82 ...

MOUNTAIN VIEW, Calif., Dec. 01, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, ...